EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease

Masaki Sato, Edward B Neufeld, Martin P Playford, Yu Lei, Alexander V Sorokin, Angel M Aponte, Lita A Freeman, Scott M Gordon, Amit K Dey, Kianoush Jeiran, Masato Hamasaki, Maureen L Sampson und 9 weitere

Journal of Clinical Investigation · 2023

DOI: 10.1172/jci165370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2023. Verfasst von Masaki Sato und 20 weiteren Autor:innen. Beteiligte Einrichtung: Lipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Artery Disease. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI DIR, Swedish Heart-Lung Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiovascular DiseasesDiabetes Mellitus, Type 2Coronary Artery DiseaseHumansLipoproteins, HDLApolipoprotein A-ICholesterol, HDLPhospholipids

Stichwörter der Autor:innen

Cardiovascular diseaseLipoproteinsMolecular diagnosisVascular Biology

Substanzen

Lipoproteins, HDLApolipoprotein A-ICholesterol, HDLPhospholipids

Autor:innen und Institutionen

  • Lipoprotein Metabolism Laboratory, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, Maryland, USA.
  • Division of Community and Family Medicine and Department of Clinical Laboratory Medicine, Jichi Medical University, Shimotsuke-City, Tochigi, Japan.
  • Biochemical Research Laboratory II, Eiken Chemical Co., Ltd., Shimotsuga-gun, Tochigi, Japan.
  • Section of Inflammation and Cardiometabolic Diseases, NHLBI, NIH, Bethesda, Maryland, USA.
  • Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Proteomics Core Facility, NHLBI, NIH, Bethesda, Maryland, USA.

Förderung

  • NHLBI DIR
  • Swedish Heart-Lung Foundation

Zitieren

APA

Sato, M., Neufeld, E. B., Playford, M. P., Lei, Y., Sorokin, A. V., Aponte, A. M., Freeman, L. A., Gordon, S. M., Dey, A. K., Jeiran, K., Hamasaki, M., Sampson, M. L., Shamburek, R. D., Tang, J., Chen, M. Y., Kotani, K., Anderson, J. L., Dullaart, R. P., Mehta, N. N., …, & Remaley, A. T. (2023). Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci165370

Vancouver

Sato M, Neufeld EB, Playford MP, Lei Y, Sorokin AV, Aponte AM, et al. Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease. Journal of Clinical Investigation. 2023. doi:10.1172/jci165370

BibTeX
@article{Sato2023,
  author = {Sato, Masaki and Neufeld, Edward B and Playford, Martin P and Lei, Yu and Sorokin, Alexander V and Aponte, Angel M and Freeman, Lita A and Gordon, Scott M and Dey, Amit K and Jeiran, Kianoush and Hamasaki, Masato and Sampson, Maureen L and Shamburek, Robert D and Tang, Jingrong and Chen, Marcus Y and Kotani, Kazuhiko and Anderson, Josephine Lc and Dullaart, Robin Pf and Mehta, Nehal N and Tietge, Uwe Jf and Remaley, Alan T},
  title = {Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  doi = {10.1172/jci165370}
}
Kostenlos starten →